Understanding cardiometabolic care for obesity is crucial for better health. Discover effective strategies and insights.

Integrative Approach to Weight Management and Metabolic Health

Disclaimer: The information presented in this post is intended for educational purposes only and should not be considered medical advice. It is not a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. The case studies presented are illustrative and individual results will vary. The treatments and medications discussed may not be suitable for everyone and should only be used under the supervision of a licensed healthcare professional.

Abstract: A Modern, Integrative Approach to Weight Management and Metabolic Health

In this educational post, I, Dr. Alex Jimenez, will guide you through the complexities of modern obesity management, drawing upon the latest evidence-based research and our clinical experience at Injury Medical Clinic. I will guide you through a comprehensive, first-person exploration of our integrative care pathways for a diverse group of patients, each presenting with unique but interconnected challenges: a 25-year-old woman with obesity, PCOS, and binge-eating disorder; a 35-year-old man with insulin resistance and male infertility; a 42-year-old perimenopausal woman with metabolic dysfunction; a 57-year-old man with type 2 diabetes and advanced cardiometabolic disease; and a 72-year-old woman with severe osteoarthritis and sarcopenia. Through their journeys, we will delve into the physiological underpinnings of obesity, including insulin resistance, hormonal dysregulation, and sarcopenia (age-related muscle loss). I will discuss advanced diagnostic tools like HOMA-IR and body composition analysis, and explain how we develop personalized, multimodal treatment plans. These plans integrate targeted nutrition, progressive physical activity, and advanced pharmacotherapy, including GLP-1/GIP receptor agonists like semaglutide and tirzepatide, as well as other medications like phentermine, naltrexone-bupropion, and lisdexamfetamine. A significant focus will be placed on the importance of our integrative care model, showcasing how the team—including myself and our Medical Director, Dr. Maria Guadalupe Cardenas, MD—collaborates to provide comprehensive care. We will also address the critical and often overlooked issues of weight bias in healthcare and the psychological barriers patients face, offering strategies to foster a supportive, patient-centered environment. This comprehensive discussion aims to illuminate a path toward sustainable health improvements, enhanced mobility, and a better quality of life for individuals with complex health challenges.

Note: This post is presented as an educational article for our clinic website; it is not a lecture. It synthesizes contemporary research using rigorous, modern, evidence-based methods and showcases the collaborative model our patients experience. For background on my clinical observations and practice philosophy, see my sciatica resource at https://sciatica.clinic/ and my professional profile at https://www.linkedin.com/in/dralexjimenez/.

The Integrative Clinical Team: Dr. Alex Jimenez and Dr. Maria Guadalupe Cardenas

Building a Multidisciplinary Foundation for Complex Metabolic Care in El Paso, Texas

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, located in El Paso, Texas, the clinical philosophy is rooted in a simple but powerful truth: complex patients deserve complex, coordinated care. No single discipline, whether chiropractic, internal medicine, nutrition, or rehabilitation, can address the full spectrum of metabolic, musculoskeletal, hormonal, and psychological challenges that patients bring to the clinic. It is precisely this recognition that drives the multidisciplinary model we practice here every day.

I am Dr. Alexander Jimenez, and my professional journey has led me to earn a series of credentials—DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST—that reflect my deep commitment to an integrative and holistic approach to patient care. My training spans chiropractic medicine, advanced practice nursing (family nurse practitioner), and functional and integrative cardiometabolic care. My clinical work focuses on metabolic optimization, spine and neuromusculoskeletal health, and injury rehabilitation within a systems-biology framework. With decades of clinical experience and a commitment to evidence-based, integrative practice, I have become a recognized voice in chronic pain management, metabolic dysfunction, hormonal imbalance, and musculoskeletal rehabilitation. My clinical observations and educational resources are publicly available at sciatica.clinic and through my professional profile at LinkedIn.

A cornerstone of our practice is my professional collaboration with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a highly respected physician, board-certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933), with over 40 years of invaluable experience as an internist. She serves as our clinic’s Medical Director and Collaborative Physician, providing essential medical oversight and direction. This partnership between a Doctor of Chiropractic (DC) and a Medical Doctor (MD) is a powerful model for integrative healthcare. It allows us to seamlessly blend the principles of chiropractic care—focusing on musculoskeletal integrity, nervous system function, and biomechanics—with the diagnostic and pharmacological expertise of internal medicine. Her role as Medical Director ensures that the clinic operates at the highest standard of medical care while providing the legal, ethical, and clinical framework for collaborative practice.

How the Collaborative Model Works

This type of multidisciplinary setup is increasingly recognized as the gold standard for integrative and injury care clinics, where patients often present with overlapping diagnoses that require simultaneous management from multiple clinical perspectives. At Injury Medical Clinic PA, the model works as follows:

• Dr. Jimenez (Chiropractic, APRN, Functional Medicine): I provide chiropractic care, functional medicine evaluation, advanced practice nursing services, musculoskeletal assessment, movement prescriptions, nutrition patterning, behavioral strategies, care coordination, and outcome tracking. My training as an APRN and FNP-BC allows me to diagnose, prescribe, order diagnostic studies, and manage patients across a broad spectrum of conditions.
• Dr. Cardenas (Internal Medicine): She provides comprehensive medical oversight, risk stratification, lab and imaging interpretation, medication selection and titration, contraceptive strategy, pregnancy planning and drug washouts, monitoring for adverse effects and drug–drug interactions, and specialist-level evaluation of complex cardiometabolic, endocrine, and systemic conditions.
• Together, the team integrates services including:

• Chiropractic spinal manipulation and soft tissue care
• Functional medicine evaluation and nutritional biochemistry
• Obesity medicine and metabolic health management
• Hormone optimization and menopausal care
• Personal injury care and rehabilitation
• Cardiometabolic risk reduction programs
• Collaborative referral to dietitians, physical therapists, and mental health professionals

This collaborative framework ensures that our patients receive a holistic and robust treatment plan that is both safe and effective, addressing all facets of their health. The clinical observations shared in this post reflect the kind of real-world, patient-centered thinking that defines our work and that has made our team trusted providers in the El Paso community for many years.

Patient Journey Case Introduction: A 25-Year-Old With Obesity, Insulin Resistance, and Probable PCOS

I first met a 25-year-old woman who works as a fitness director and lives an active lifestyle. Despite her high activity, she reported lifelong weight struggles with cycles of loss and regain, escalating to her highest weight at presentation. She reported:

• BMI of 37.5 with central adiposity (elevated waist circumference, apple-shaped pattern).
• Clinical signs of insulin resistance: acanthosis nigricans, skin tags.
• Hyperandrogenism indicators: cystic acne, hirsutism (upper lip hair).
• Ovulatory dysfunction: infrequent, irregular menses since adolescence.
• Metabolic labs: fasting insulin 36.1 µIU/mL, fasting glucose 107 mg/dL, A1c 6.0%, elevated triglycerides, low HDL, elevated LDL, and elevated liver enzymes; HOMA-IR 9.5 (marked insulin resistance).
• Eating pattern: highly restrictive caloric targets (~1200 kcal), anxiety when exceeding this, evening cravings, and intermittent binge episodes 1–2 evenings per week.
• Reproductive context: sexually active for 5 years without contraception, believes she “can’t get pregnant,” and wishes for future fertility.

In my examination and review with Dr. Cardenas, she met 2 of the 3 Rotterdam criteria for PCOS (hyperandrogenism and ovulatory dysfunction). She had cardiometabolic risk amplification consistent with insulin resistance and prediabetes. She also presented with binge-eating disorder features.

Why this matters

• PCOS is a chronic, lifelong syndrome with persistent cardiometabolic risk beyond menopause, driven by insulin resistance and hyperandrogenism (Legro et al., 2013; Fauser et al., 2012).
• Insulin resistance impairs weight loss, increases hepatic lipogenesis, fuels dyslipidemia, and worsens ovulatory dysfunction (Dunaif, 1997; Taylor, 2021).
• Restrictive eating and binge cycles heighten stress reactivity, dysregulate appetite signals (ghrelin/leptin), and perpetuate weight cycling with preferential fat regain and muscle loss (Montani et al., 2015; Dulloo & Montani, 2015).

Diagnostic Framing: Insulin Resistance, PCOS, Dyslipidemia, and Binge-Eating Disorder

Key clinical impressions at baseline:

• Class II obesity with central adiposity and metabolic syndrome features.
• Probable PCOS by clinical criteria (no need to delay treatment with exhaustive imaging when clinical criteria are satisfied and symptoms are significant).
• Prediabetes (A1c 6.0%) with hyperinsulinemia (fasting insulin 36.1 µIU/mL) and HOMA-IR 9.5.
• Atherogenic dyslipidemia typical of insulin resistance: elevated triglycerides, low HDL, elevated LDL.
• Elevated liver enzymes consistent with metabolic dysfunction-associated steatotic liver disease risk (MASLD; formerly NAFLD).
• Binge-eating disorder by symptoms and validated screening.

How I screen for binge eating in practice

• I incorporate the BEDS-7 (Binge Eating Disorder Screener-7) to assess frequency of unusually large food intake, perceived loss of control, and associated distress (Herman et al., 2016). Scores >5 suggest binge-eating disorder and prompt structured intervention and, when appropriate, pharmacotherapy.

Physiological linkages

• Hyperinsulinemia and androgen excess create a feed-forward loop: insulin stimulates ovarian theca cells, increasing androgen production; androgens worsen visceral adiposity and insulin resistance (Dunaif, 1997; Azziz et al., 2016).
• Central adiposity produces proinflammatory adipokines (e.g., TNF-α, IL-6) and reduces adiponectin, reducing insulin sensitivity and impairing ovulatory signaling (Kershaw & Flier, 2004).
• Restrictive eating raises cortisol, disrupts HPA axis tone, and primes reward-seeking circuits, amplifying binge risk (Adam & Epel, 2007; Berthoud, 2011).

Case Study 1: George – Unraveling the Links Between Stress, Hormones, and Male Fertility

Let’s begin by meeting George. His story is one that I see with increasing frequency in my practice—a story where the pressures of modern life manifest as complex physiological problems.

George is a 35-year-old man who works as a project manager for a tech company. He doesn’t smoke, which is a positive starting point. He and his spouse are trying to have a second child, but they are facing challenges, much like they did with their first. This is a significant source of emotional strain for both of them. When he first came to see me, he reported several concerning symptoms:

• Feelings of depression and anxiety.
• A recent diagnosis of low sperm count, which is a primary driver of his current distress.
• Elevated blood pressure
• Significant stress, stemming from both his demanding job and his personal life.

As we delved deeper into his daily life, a more detailed picture emerged. He’s aiming for a promotion, which adds a layer of professional pressure. His commute is long, eating into his personal time and adding to his daily stress load. At his tech company, free food and drinks are abundant, a common perk that often leads to unintentional overconsumption of processed foods and sugary beverages. On top of this, he and his spouse are navigating the stressful process of buying a new home in a better school district for their family.

The news of his low sperm count was particularly distressing for him. Compounding this worry is his concern over his elevated blood pressure, a fear magnified by his family history—his father was diagnosed with heart failure, which George correctly understands is linked to untreated hypertension. He also shared, with some hesitation, that he experiences occasional erectile dysfunction, which he attributes to stress. This constellation of symptoms paints a picture of a man whose body is struggling under the weight of chronic physiological and psychological stress.

Initial Clinical Assessment and Lab Findings

About three months before our consultation, George had a complete physical with another practitioner. The findings from that visit, combined with our own initial assessment, were revealing.

Concerning Trends and Vital Signs:

• Weight Gain: There was a noticeable upward trend in his weight.
• Waist Circumference: His waist measured at an elevated level, a key indicator of visceral adiposity (fat stored around the internal organs), which is a major risk factor for metabolic disease.
• Blood Pressure: His readings were consistently in the elevated range, confirming his concerns about hypertension.
• Poor Sleep: He reported not sleeping well, feeling unrested upon waking.
• Increased Hunger: He was feeling hungry frequently and expressed shame about his inability to control his appetite. This feeling of lost control is a common and powerful psychological barrier for many patients.

He shared that he and his spouse are trying to adopt healthier habits together, but he worries about how she perceives the fertility issues, adding another layer of emotional complexity.

Laboratory Results:

Here is where the objective data began to connect the dots of his symptomatic complaints:

• Fasting Glucose & Fasting Insulin: Both were significantly increased. This is a classic sign that the body is struggling to manage blood sugar.
• HOMA-IR (Homeostasis Model Assessment for Insulin Resistance): We calculated his HOMA-IR score, which came out to 1.

To put this in perspective, a HOMA-IR score is a calculation using fasting glucose and fasting insulin levels to quantify the degree of insulin resistance. A score above 1.9 is generally considered indicative of early insulin resistance, while a score above 2.9 is a stronger indicator. George’s score of 3.1 firmly places him in the insulin resistance category. This means his cells are becoming “numb” to the effects of insulin, forcing his pancreas to pump out more and more of the hormone to keep blood sugar in check. This state of hyperinsulinemia is a major driver of fat storage, inflammation, and further hormonal chaos.

• Lipid Panel: His cholesterol levels were slightly elevated, pointing towards dyslipidemia, another hallmark of metabolic syndrome.
• Kidney and Electrolyte Function: These were within normal limits, which was reassuring.

However, I noted some critical missing pieces in his previous lab work. There was no Hemoglobin A1c (HbA1c) to assess his average blood sugar over the past three months, no thyroid panel to rule out thyroid dysfunction as a cause for his fatigue and weight gain, and no liver panel to check for signs of fatty liver disease, a common consequence of insulin resistance. We needed to order these to get a complete picture of his metabolic health.

Identifying Health Risks and Patient-Centered Goals

Based on this initial information, we identified several key areas of concern:

• Cardiometabolic Risk: His elevated blood pressure, insulin resistance, dyslipidemia, and visceral adiposity put him at high risk for developing type 2 diabetes and cardiovascular disease.
• Hormonal Imbalance: The interplay between stress, obesity, and insulin resistance was clearly impacting his endocrine system.
• Mental and Emotional Health: His reported depression, anxiety, and stress were not just symptoms but also drivers of his physiological condition.
• Substance Use/Coping Mechanisms: We needed to explore how he was managing his stress. Was he turning to food, alcohol, or other substances?
• Lifestyle Factors: A deep dive into his nutrition, physical activity, and sleep habits was necessary.

Most importantly, we needed to understand what mattered to the patient. A treatment plan is only effective if it aligns with the patient’s own goals. When we asked him, his priorities were clear, and notably, “losing weight” was not his primary stated goal. Instead, he wanted to:

1. Improve his heart health and prevent the fate his father faced.
2. Prevent the onset of diabetes.
3. Improve his fertility.
4. Manage his stress more effectively.
5. Have enough energy to be an active and engaged father.

This is a crucial distinction. By focusing on his intrinsic motivations, we could frame our interventions in a way that resonated with him, moving beyond the simple and often stigmatizing focus on the number on the scale. For a young woman like the PCOS patient, a key goal was future fertility, while for George, it was also fertility, alongside preventing the chronic diseases that afflicted his father. This highlights the need to align on patient-centered and measurable goals. For instance, even a 5–10% weight loss meaningfully improves insulin sensitivity, triglycerides, HDL, blood pressure, and A1c and can restore ovulation in PCOS (Knowler et al., 2002; Wilding et al., 2021; Moran et al., 2011).

The Vicious Cycle: Chemical vs. Character

One of the first and most important conversations I had with George was about the concept of “Chemical versus Character.” He had expressed deep shame about his inability to control his hunger. This is a story I hear every day. Patients internalize their body’s physiological signals as a personal or moral failing. They believe if they just had more willpower, more discipline, or a stronger character, they could overcome their cravings and weight gain.

I explained to George that what he was experiencing was not a failure of character, but a result of powerful chemical signals being driven by his underlying physiology. This understanding is profoundly liberating. It helps to release the internal bias, stigma, shame, and guilt that so many people carry, which in itself is a major source of stress.

We walked through the positive feedback cycle of obesity and hormone changes. In this context, “positive” doesn’t mean good; it means amplifying. The obesity drives the hormone changes, and the hormone changes, in turn, drive more obesity. Here’s how it works:

The Hormonal Cascade of Obesity and Stress

• Increased Adipose Tissue and Its Endocrine Role: As a person accumulates excess adipose (fat) tissue, especially visceral fat, it doesn’t just sit there passively. Adipose tissue is a highly active endocrine organ. One of its key functions is producing an enzyme called aromatase.

• Aromatase and Hormone Conversion: Aromatase converts androgens, like testosterone, into estrogens. In men, this leads to a dangerous imbalance: testosterone levels decrease while estrogen levels increase. Low testosterone contributes to fatigue, low mood, decreased muscle mass, and, critically for George, impaired sperm production (Katib, 2015). High estrogen can further promote fat storage, creating a self-perpetuating cycle.

• Cortisol, Insulin, and Appetite: Chronic stress—from his job, commute, and personal worries—keeps his cortisol levels chronically elevated. Cortisol is our primary stress hormone. In short bursts, it’s essential for survival. But when it’s high all the time, it wreaks havoc.

• Chronically high cortisol signals the body to store energy, particularly as visceral fat around the abdomen.
• It also directly drives up appetite and cravings, especially for high-sugar, high-fat “comfort foods.”
• Simultaneously, the underlying insulin resistance means that even though his body is flooded with insulin, it can’t use glucose effectively for energy. This state of perceived cellular starvation sends powerful hunger signals to the brain.

• The Dysregulation of Hunger and Satiety Hormones: This process throws the delicate balance of our main appetite-regulating hormones into disarray.

• Ghrelin: Known as the “hunger hormone,” ghrelin is produced in the stomach and signals the brain that it’s time to eat. In George’s state, his ghrelin levels are chronically elevated, making him feel constantly hungry.
• Leptin: This is the “satiety hormone,” produced by fat cells to tell the brain, “We have enough energy stored; you can stop eating.” However, in a state of obesity and inflammation, the brain can become leptin resistant. Similar to insulin resistance, the signal is being sent, but the brain isn’t receiving it. So, despite having ample energy stores, his brain thinks he’s starving.
• GLP-1 (Glucagon-Like Peptide-1): This is another crucial satiety hormone, released from the gut after eating. It slows stomach emptying, reduces appetite, and improves insulin sensitivity. In states of metabolic dysfunction, GLP-1 signaling is often impaired.
• The result of this hormonal storm is a dramatic increase in appetite and a sharp decrease in satiety. This is a chemical reality, not a character flaw.

• Inflammation and Self-Blame: The excess adipose tissue also releases inflammatory molecules called adipokines. This chronic, low-grade inflammation further worsens insulin resistance and contributes to a feeling of malaise and fatigue. The inability to control cravings leads to more self-blame and a negative internal dialogue, which further increases stress and elevates cortisol. And so, the vicious cycle continues to spin, gaining momentum with each rotation.

Understanding this complex interplay was a breakthrough for George. It shifted his perspective from self-blame to curiosity and empowered him to become an active participant in his own recovery.

Transform Your Body!- Video

Case Study 2: Lynn – Navigating Perimenopause, Grief, and Metabolic Health

Now, let’s turn our attention to Lynn. Her case highlights a different but equally common set of challenges, centered around the hormonal transition of perimenopause.

Lynn is a 42-year-old non-smoker who works full-time as an event planner. She came to our clinic with a cluster of symptoms that I’m sure many practitioners will find familiar:

• Fatigue and “Brain Fog”: A profound sense of mental cloudiness and difficulty concentrating.
• Poor Sleep: Difficulty falling or staying asleep.
• Mood Swings: Increased irritability and emotional lability.
• Hot Flashes: Sudden feelings of intense heat, a classic vasomotor symptom of perimenopause.
• A 20-pound weight gain that she was very concerned about.

Her history revealed several important details. She had her first child at age 35, but it was after a difficult time conceiving, which may suggest a pre-existing hormonal imbalance. She reported that her periods had been irregular for most of her adult life, often heavy and accompanied by severe mood changes and worsened depression, pointing towards a possible history of PMDD (Premenstrual Dysphoric Disorder) or other underlying issues.

The Weight of Grief and Medical Distrust

A significant life event was casting a long shadow over her health: she had lost her father to heart disease just six months ago. We needed to be acutely aware of the grief she was processing. Furthermore, her trust in the medical system was frayed. We were her third primary care provider in the last 18 months due to provider turnover at her previous clinic. This lack of continuity of care is a major barrier to effective treatment.

She felt her previous concerns had been dismissed. When she brought up her perimenopausal symptoms, she felt they were brushed aside. When she expressed concern about her weight gain, she was told she just needed to pay more attention to her diet and exercise. This dismissive advice left her feeling lonely and unheard, a common experience for many women in this life stage.

Clinical and Laboratory Findings for Lynn

Vital Signs and Lab Work:

• Blood Pressure: Her blood pressure was slightly elevated.
• Waist Circumference: Her waist circumference was elevated (above the 35-inch threshold for women), indicating increased visceral adiposity and metabolic risk.
• Lab Results:

• Cholesterol Panel and HbA1c: Both indicated emerging metabolic issues, consistent with her weight gain and elevated waist circumference.
• Thyroid and Kidney Function: Both were normal.
• Liver Enzymes: Her liver enzymes were slightly elevated, which, like with George, raises concern for nonalcoholic fatty liver disease (NAFLD).

• Screenings: She was up to date on all her age-appropriate health screenings, which was excellent.

Health Risks and Considerations:

• Cardiovascular Disease: Her elevated blood pressure, dyslipidemia, visceral adiposity, and family history (father with heart disease) put her at increased risk.
• Type 2 Diabetes: Her HbA1c results indicated she was on the path towards metabolic syndrome and diabetes.
• Perimenopausal Transition: Her symptoms were classic for this hormonal shift.
• Grief and Mental Health: The recent loss of her father was a significant psychological stressor.

Lynn’s Health Goals: Reclaiming Her Mind and Body

When we discussed her goals, Lynn was clear and articulate. She was tired of “feeling like she’s lost her mind,” a powerful description many women use for the cognitive effects of perimenopause. Her priorities were:

1. Alleviate her perimenopausal symptoms, especially the brain fog, mood swings, and poor sleep.
2. Reduce her blood pressure.
3. Prevent further weight gain and reduce her visceral fat.
4. Decrease her long-term risk for cardiovascular disease.

The Physiology of Perimenopause and Metabolic Dysfunction

How Declining Estrogen Reshapes the Metabolic Landscape

Perimenopause is the transitional phase preceding menopause, typically beginning in a woman’s mid-to-late forties, during which ovarian function begins to decline and estrogen and progesterone levels fluctuate erratically before ultimately falling. This phase can last anywhere from two to ten years and is associated with a constellation of symptoms and physiological changes that have profound implications for metabolic health, cardiovascular function, body composition, cognitive clarity, and overall quality of life (Santoro et al., 2021).

To fully appreciate why perimenopause demands serious clinical attention in the context of obesity and cardiometabolic risk, it is essential to understand estrogen’s role as a metabolic hormone. This role extends far beyond its reproductive functions.

Estrogen as a Metabolic Regulator

Estradiol (E2), the predominant form of estrogen during the reproductive years, exerts its effects through estrogen receptors (ERα and ERβ) that are distributed throughout virtually every tissue in the body, including adipose tissue, skeletal muscle, liver, pancreas, brain, and the cardiovascular system. Through these receptors, estrogen:

• Regulates insulin sensitivity. Estradiol enhances insulin receptor signaling and promotes glucose uptake in peripheral tissues. As estrogen levels decline during perimenopause, insulin resistance increases, raising the risk of type 2 diabetes and metabolic syndrome (Mauvais-Jarvis et al., 2013).
• Governs fat distribution. Estrogen promotes the preferential storage of fat in the gluteofemoral (hip and thigh) region—the so-called “android” fat pattern, which is metabolically less harmful than visceral fat. As estrogen declines, fat redistribution shifts toward the visceral compartment, dramatically increasing cardiometabolic risk. This is why many women notice a significant increase in belly fat during perimenopause even without significant changes in their eating or exercise habits (Davis et al., 2012).
• Supports energy expenditure and mitochondrial function. Estrogen promotes mitochondrial biogenesis and oxidative phosphorylation, meaning that as estrogen declines, cellular energy production becomes less efficient, resting metabolic rate decreases, and fatigue increases. This partially explains the profound fatigue that Lynn and many perimenopausal women experience.
• Protects lean muscle mass. Estrogen has anabolic effects on skeletal muscle, promoting muscle protein synthesis and reducing muscle protein breakdown. The perimenopausal decline in estrogen accelerates sarcopenia (age-related muscle loss) at a time when it is already beginning due to the natural aging process after age thirty (Sipila et al., 2021).
• Modulates appetite and food reward. Estrogen receptors in the hypothalamus regulate hunger-signaling pathways, including those involving leptin and neuropeptide Y. Declining estrogen can dysregulate these pathways, increasing appetite and reducing the rewarding sensation of food—contributing to increased caloric intake and weight gain (Asarian & Geary, 2013).
• Supports cardiovascular health. Estrogen promotes endothelial function, reduces LDL oxidation, supports HDL production, and has anti-inflammatory effects on the vascular wall. The decline in estrogen during perimenopause is associated with accelerated cardiovascular risk, which is why women’s cardiovascular disease incidence rises sharply after the menopausal transition (Mendelsohn & Karas, 1999).

Case Study 3: Dolores’s Battle with Osteoarthritis and Sarcopenia

Now, let’s shift our focus to another patient, Dolores. Her case highlights a different but equally common set of challenges, particularly those faced by older women.

Dolores is a 72-year-old retired wealth advisor who is eager to begin a new chapter of her life: traveling. However, her plans are severely hampered by her health.

Presenting Clinical Picture

• Primary Complaint: Severe osteoarthritis (OA) in both knees. The pain and joint damage have significantly limited her mobility.
• Immediate Goal: She desires a total knee replacement for both knees to regain her freedom of movement. However, she has been told she must first reduce her weight to achieve a Body Mass Index (BMI) below 40 to qualify for the surgery.
• Medical History: Her pertinent history includes hyperlipidemia (high cholesterol, for which she takes rosuvastatin), insomnia (managed with trazodone), and her knee OA (for which she uses diclofenac, an NSAID).
• Weight History: Dolores reports a very common pattern. She maintained a stable weight until she entered perimenopause. At that point, she began to gain weight, particularly central adiposity (fat around her midsection), and has been on an upward trajectory ever since. Past attempts at weight loss through portion control, eliminating sweets, and increasing activity have been short-lived, always ending in weight regain. This yo-yo pattern is typical and speaks to the powerful biological and hormonal forces at play.

Baseline Health Behaviors and Labs

• Nutrition: She eats three meals a day but consumes very little protein. She enjoys fruits and vegetables but also loves sweets, finding them especially difficult to resist in the evening. This combination—low protein, high sugar—is a recipe for muscle loss and fat gain.
• Physical Activity: Her severe knee pain restricts her activity. She can swim for 20 minutes, three times a week, which is excellent as it is a non-weight-bearing exercise.
• Sleep: She has a long-standing history of insomnia, which is now much improved with trazodone. Quality sleep is crucial for hormonal regulation, muscle repair, and appetite control, so managing this is a key part of her overall plan.
• Social Habits: She is a non-smoker and drinks alcohol only occasionally.

When we look at her initial labs and measurements, she appears, on the surface, to be “metabolically healthier” than other patients at baseline.

• Fasting Insulin: Her fasting insulin is 8.4 µU/mL. This is slightly elevated but not nearly as high as others, suggesting a lesser degree of insulin resistance.
• BMI and Body Composition:

• Her BMI is 41.5, just over the surgical cutoff.
• Her body fat percentage is 56.8%, which is extremely high.
• Her skeletal muscle mass is a mere 15.1%, placing her in the 2nd percentile for women her age. This is a critical finding: Dolores has severe sarcopenia.

• Visceral Fat and Body Shape: Her visceral fat is 2.3 liters. She has a gynoid (“pear-shaped”) fat distribution pattern, but with the added central adiposity common after menopause.
• Metabolic Markers: Because she has maintained some level of physical activity (swimming) and has a healthier diet in some respects (high fruit and vegetable intake), her lipids and A1c are currently in a good range.

Identifying the Health Risks and Inequities

Our primary concern is preventing her from tipping over into full-blown metabolic disease. But just as important is recognizing the unique challenges and health inequities she faces.

1. Systemic Health Inequities: Dolores is at the intersection of three factors that often lead to suboptimal care: she is female, she is older, and she has obesity. Research and my own clinical observations confirm that patients with these characteristics are frequently dismissed by the healthcare system (Puhl & Heuer, 2009). Their concerns are minimized, their symptoms are attributed solely to their weight, and they are often not offered the full range of evidence-based treatments. Many of these women come to expect this treatment and, as a result, don’t advocate for themselves. It is my responsibility as her clinician to be acutely aware of this and to be her proactive advocate.
2. Progressive Immobility and Sarcopenia: The vicious cycle is clear: her knee pain prevents her from exercising, which worsens her sarcopenia and contributes to weight gain. The increased weight, in turn, puts more stress on her knees, worsening the pain and accelerating the joint damage. We must break this cycle.
3. Deteriorating Quality of Life: Her immobility and pain are robbing her of her retirement dreams. This is not a cosmetic issue; it’s about function, independence, and joy.
4. Future Cardiometabolic Risk: While her labs look relatively good now, her high body fat percentage, central adiposity, and sarcopenia put her on a direct path toward developing type 2 diabetes, worsening hypertension, and cardiovascular disease if left unaddressed.

Introducing Amit: A Case Study in Sarcopenic Obesity and Cardiometabolic Disease

The case of Amit—a fifty-seven-year-old male of North African ancestry, married, with two college-aged children, working as a manager at a tire factory—offers a profoundly different but equally instructive clinical portrait. Where Lynn’s case illustrated the hormonal and metabolic consequences of perimenopause, Amit’s case illustrates the convergence of multiple advanced cardiometabolic conditions in a patient whose obesity has been present since early adulthood and whose disease burden reflects both genetic predisposition and decades of metabolic dysregulation.

Amit’s Medical History: A Constellation of Interconnected Diagnoses

Amit’s pertinent medical history includes:

• Type 2 diabetes mellitus—treated with both basal and bolus insulin plus metformin
• Myocardial infarction (MI) three years prior—the single most significant event in his health history, prompting smoking cessation
• Stage 2A peripheral artery disease (PAD) with intermittent claudication—indicating established atherosclerotic disease in the lower extremities
• Obstructive sleep apnea (OSA)—managed with CPAP
• Hypertension—on lisinopril
• Hyperlipidemia—on rosuvastatin
• Stage 2 Metabolic-Associated Steatotic Liver Disease (MASLD)—formerly called NAFLD/NASH, representing significant hepatic fat accumulation and inflammation.
• Low testosterone (hypogonadism)—on testosterone therapy
• Erectile dysfunction—on tadalafil
• Former smoker—quit after his MI

Each of these diagnoses is individually significant. Together, they form a metabolically devastating picture in which each condition both results from and perpetuates the others. Insulin resistance drives visceral fat accumulation, which drives inflammation, which drives atherosclerosis, which caused the MI and drives PAD. Sleep apnea worsens insulin resistance and hypertension. Low testosterone accelerates muscle loss and fat gain. MASLD reflects and contributes to systemic dyslipidemia and insulin resistance. Every condition feeds every other.

Body Composition Analysis in Sarcopenic Obesity

The body composition data obtained for Amit tells a story that the BMI alone cannot tell:

• BMI 38.4—Class 2 obesity, significant but not the most clinically informative metric
• 7% body fat—the majority of his body weight is fat mass; this is extremely elevated
• Skeletal muscle mass 20.7%—placing him in the fourth percentile compared to age-, weight-, and height-matched peers; a profoundly low level of muscle mass
• Visceral fat 4.4 liters (measured by bioimpedance)—significantly elevated; visceral fat is the metabolically active, inflammatory fat depot most strongly associated with cardiometabolic disease
• Waist circumference 51.25 inches—far exceeding the clinical threshold (greater than 40 inches in men) associated with metabolic syndrome

The combination of high fat mass and low muscle mass is the definition of sarcopenic obesity—a condition that carries significantly higher health risks than either obesity or sarcopenia alone. The fact that Amit ranks in the fourth percentile for skeletal muscle mass relative to his peers is a striking clinical finding. It means that 96% of men his age, with his weight and height, have more muscle mass than he does.

The Acanthosis Nigricans, Skin Tags, and Physical Examination Findings

The physical examination findings reported for Amit include:

• Acanthosis nigricans—a velvety, hyperpigmented thickening of the skin in the neck folds, axillae, and groin, which is a cutaneous marker of severe insulin resistance.
• Skin tags (acrochordons)—also associated with insulin resistance and hyperinsulinemia.
• Enlarged liver (hepatomegaly)—consistent with his diagnosis of stage 2 MASLD.
• 1+ pitting edema in lower extremities—indicating impaired venous return.

Each of these physical findings is not isolated—together they form a coherent clinical narrative of advanced metabolic syndrome with multi-organ involvement.

Stepwise Care Plan: Nutrition, Movement, Medication, and Behavioral Stability

I prefer sequential rollouts to stabilize each pillar of a patient’s care plan. This allows us to attribute effects and avoid overwhelming the patient. This strategy applies to George, Lynn, Dolores, Amit, and our 25-year-old with PCOS.

Shared Decision-Making: Why the Sequence of Treatment Matters

One of the most instructive questions in clinical weight management is not simply what to treat, but in what order to treat it. When considering a perimenopausal woman like Lynn, the decision to initiate menopausal hormone therapy (MHT) before an obesity medication was made for several well-grounded reasons:

• Perimenopause was her primary concern. Shared decision-making begins with listening. Addressing her most pressing concern first builds therapeutic trust and adherence.
• She met clinical criteria for MHT. She was within the “window of opportunity” for hormone therapy, where benefits are most robust (Manson et al., 2017).
• Starting one medication at a time allows for cleaner attribution of adverse effects.
• Hormonal optimization may itself support metabolic improvement. Correcting the hormonal deficit can create a more receptive physiological environment for subsequent weight management interventions.

1. Nutrition Recalibration

For all our patients, the first step is a nutritional intervention. We shift from calorie-obsession to pattern-based, protein-forward, carbohydrate-restricted eating tailored for insulin resistance.

• Target 4–5 small meals/day, spaced every 3–4 hours, minimizing long fasting windows that can provoke evening hyperphagia and binges.
• Protein: 90–100 g/day (at least 1.2–1.6 g/kg ideal body weight), anchored at breakfast to blunt diurnal hunger curves and improve glycemic responses (Leidy et al., 2015). This is crucial for both Amin’s and Dolores’s sarcopenia.
• Fiber: Emphasize non-starchy vegetables and whole fruit to 50–100 g/day total carbohydrate (net carbs individualized).
• Minimize ultra-processed foods, refined starches, sweets, and limit alcohol.
• Rationale: Lower glycemic load reduces postprandial insulin excursions; protein supports GLP-1/PYY responses, stabilizes appetite, and protects lean mass during weight loss (Hall & Guo, 2017). For Amit, we specifically recommend a Mediterranean dietary pattern, which aligns with his North African heritage and has strong evidence for cardiovascular benefit (Estruch et al., 2018).

2. Movement Dosing and Autonomic Support

Physical activity is a cornerstone, but it must be tailored to the patient’s ability.

• For active patients, like our 25-year-old with PCOS, we maintain their robust routine.
• For sedentary or pained patients, like George, Dolores, and Amit, we start small. We encouraged George to take the stairs at work. For Dolores and Amit, with significant mobility limitations, a referral to Physical Therapy (PT) is key.
• A PT can design programs for strengthening supportive muscles (as in Dolores’s knee OA) and supervised exercise for conditions like Amit’s claudication. Cycling (stationary bike) is often a great option.
• Add insulin-sensitizing micro-bouts: 10-minute brisk walks daily (postprandial preferred), progressing as tolerated (DiPietro et al., 2013).
• Strength Training: All patients are encouraged to add resistance training at least twice weekly to preserve and build metabolically active muscle mass.

3. Medical Therapy with Internal Medicine Oversight

After setting nutrition and movement foundations, we introduce medical therapy under Dr. Cardenas’s supervision.

• Metformin: For patients like our 25-year-old with PCOS/prediabetes, we initiate Metformin ER, titrating as tolerated. Metformin reduces hepatic gluconeogenesis, improves peripheral insulin sensitivity, and can aid weight stabilization in PCOS (Morley et al., 2017).
• Hypertension Management: For George and Amit, controlling blood pressure with appropriate medication (like lisinopril for Amit) is an immediate priority.
• Hormone Replacement: For Lynn, we started transdermal estrogen and progesterone to address her primary perimenopausal symptoms. Transdermal delivery is preferred to avoid first-pass hepatic metabolism and reduce VTE risk (Canonico et al., 2007).
• Obesity Pharmacotherapy: Based on the patient’s profile and needs, we introduce powerful medications to assist with weight management.

• Bupropion-Naltrexone: A good choice for George’s cravings and depression and Dolores’s evening sweet cravings (Guerin & Billes, 2016).
• GLP-1/GIP Agonists (Semaglutide/Tirzepatide): These are game-changers. For Amit, semaglutide 2.4 mg (Wegovy) was chosen due to the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events in patients with pre-existing cardiovascular disease (Lincoff et al., 2023). For our PCOS patient and Lynn, tirzepatide was chosen for its potent dual-agonist effects on weight and metabolism (Frias et al., 2021).

• Lisdexamfetamine: If binge-eating persists despite GLP-1/GIP stabilization, as in the case of our 25-year-old, we consider this FDA-approved medication with careful monitoring (McElroy et al., 2015).
• Deprescribing Insulin: For Amit, a crucial step was tapering and stopping his exogenous insulin as the semaglutide improved his glycemic control. Continuing insulin would have risked hypoglycemia and perpetuated weight gain.

4. Behavioral Stability, Sleep, and Mental Health

• Sleep Optimization: For all patients, but especially George and our PCOS patient, we emphasize 7-9 hours of consistent, high-quality sleep to normalize leptin/ghrelin signaling (Taheri et al., 2004). For patients like George and Amit with suspected sleep apnea, a sleep study is essential.
• Stress Management: We made meditation accessible for George by suggesting a three-minute guided app in his car.
• Mental Health Support: We referred Lynn to a therapist for grief counseling and encouraged ongoing therapy for all patients to address emotional eating, anxiety, and the psychological burden of chronic disease.

Addressing the Barriers: A Patient-Centered and Trauma-Informed Approach

A plan is only as good as a patient’s ability to implement it. Dolores, in particular, faced a significant barrier: a deep-seated fear of going to PT because she believed she would be judged for her weight, as she had been by healthcare providers in the past. Her fear is valid and born of negative experiences with weight bias.

My response to this must be one of empathy, validation, and empowerment.

• Validate and Listen: The first step is to listen without judgment. I say things like, “Thank you for telling me that. I can completely understand why you would feel that way. Your experiences are real, and your feelings are valid.”
• Advocate for the Patient: I explicitly tell her, “I am on your side. We are a team. I will advocate for you.” This might involve me personally calling the physical therapy clinic or the orthopedic surgeon’s office to reframe the conversation from one of patient blame to one of collaborative problem-solving.
• Coach and Role-Play: We work together to prepare her for these appointments. We role-play conversations, transforming her from a passive recipient of judgment into an empowered partner in her own care.

My colleague’s point about BMI requirements for surgery is critically important. These blanket cutoffs are often not patient-centered and can feel so discouraging that patients give up. Advocating against these rigid, non-evidence-based protocols is part of our job as clinicians.

Why Integrative Chiropractic Care Belongs in Metabolic Care

Integrative chiropractic care is not a standalone weight-loss tool; it is a movement, pain, and autonomic optimization modality that elevates adherence to the core metabolic interventions. Within this comprehensive plan, my role as a chiropractor is to address the crucial connection between the nervous system and the body’s overall function.

• Pain and Mobility: Chronic pain and limited mobility impose energetic and psychological barriers to consistent activity. For patients like Dolores with severe OA or Amit with claudication, musculoskeletal pain is the primary obstacle. By addressing lumbopelvic, thoracic, and rib biomechanics, I reduce mechanical load and pain. Patients walk more, lift more, and sit less, multiplying daily energy expenditure and insulin sensitivity gains. My clinical observations over decades, including reflections shared across my resources (see sciatica.clinic), suggest that reducing mechanical pain and improving segmental motion enhances patients’ capacity to sustain regular, insulin-sensitizing activity.
• Autonomic Nervous System (ANS) Balance: Chronic stress, like George was experiencing, places an immense load on the ANS, leaving patients stuck in a state of sympathetic dominance (“fight or flight”). Chiropractic adjustments, particularly in the upper cervical and thoracic regions, can help modulate the ANS, promoting a shift to parasympathetic activity (“rest and digest”). This can lead to a reduction in resting heart rate and blood pressure, improved heart rate variability (HRV), enhanced digestive function, and a subjective feeling of calmness and well-being.
• Neuromuscular Re-education: For patients with sarcopenic obesity like Amit and Dolores, chiropractic rehabilitation is critical. We address joint misalignments and compensatory movement patterns, making their physical therapy and strength training safer and more effective. Graded exposure and neuromuscular re-education build confidence and reduce fear-avoidance, stabilizing the actionable lifestyle domain where medications exert their greatest synergistic benefits.

In multidisciplinary care, the chiropractor’s role is a movement and function specialist, complementing the internist’s medical management. With Dr. Cardenas coordinating safety and metabolic pharmacology, I ensure our patient can physically and neurologically engage the program at a high level—and keep doing so over months and years.

Clinical Outcomes: The Power of an Integrated Approach

The journeys of our patients demonstrate what is possible with a comprehensive, patient-centered, and integrative approach.

The 25-Year-Old with PCOS: Two-Year Outcomes

• Total weight reduction: 24.1% from baseline.
• Fasting insulin: 8.4 µIU/mL (normalized from 36.1).
• HOMA-IR: normalized.
• A1c: 5.2% (normoglycemic range, down from 6.0%).
• Binge-eating: effectively resolved with the addition of lisdexamfetamine.
• Fertility Planning: The patient is now well-positioned to contemplate pregnancy with lower cardiometabolic risk and improved ovulatory potential.

George (Male Infertility): One-Year Outcomes

• A New Baby on the Way: His spouse was pregnant, a direct result of improving his metabolic and hormonal health.
• HOMA-IR: Dropped from 3.1 to 64 (insulin sensitive).
• HbA1c: Moved from 9% (prediabetic) to the normal range.
• Blood Pressure: Well-controlled.
• Medication: Found his “sweet spot” on semaglutide 1.7 mg weekly, sufficient to control appetite without needing the maximum dose.

Amit (Cardiometabolic Syndrome): One-Year Outcomes

• Weight Loss: Achieved a 3% reduction in total body weight.
• Insulin: Successfully tapered off all exogenous insulin.
• Fasting Insulin: Dropped to 1 µU/mL from a much higher baseline on insulin.
• HbA1c: Decreased to 0% (from uncontrolled diabetes).
• Body Composition: Body fat decreased from 56.7% to 1%, while skeletal muscle mass percentile increased from 4th to 25th.
• Function: Claudication pain is minimal, and he enjoys daily exercise.

Dolores (Osteoarthritis): One-Year Outcomes

• Surgery and Recovery: Successfully had her first knee replacement with no complications and is planning her second.
• Body Composition: Achieved a 7% body weight reduction while increasing her muscle mass percentile from 2nd to 10th.
• Labs: Fasting insulin is now in the normal range.
• Quality of Life: Her ultimate goal is within reach: she is planning her trip to Europe.

What Success Looks Like in Our Clinic

• Biomarkers: Fasting insulin trending to single digits, HOMA-IR into normal range, A1c into the low 5s, triglycerides down, HDL up, ALT/AST normalization.
• Symptoms: Acne and hirsutism reduced, cycles become more regular, energy improves, and sleep stabilizes.
• Behavior: Binge episodes diminish or resolve; anxiety around calories subsides; movement becomes routine and enjoyable.
• Structure: Chiropractic sessions reduce pain barriers; internal medicine oversight ensures safe and effective pharmacotherapy; functional supports keep the system resilient.

Conclusion: The Power of Integrative and Compassionate Care

The cases of these patients powerfully illustrate that obesity is a complex, chronic disease that requires a sophisticated, multifaceted, and deeply compassionate approach. At Injury Medical Clinic, our integrative model—combining chiropractic care for musculoskeletal function, medical oversight from Dr. Cardenas for complex disease management and pharmacotherapy, and a functional medicine lens to seek root causes—allows us to create these kinds of life-changing outcomes.

By treating obesity with the seriousness and scientific rigor it deserves, we can help our patients not just lose weight, but regain their health, their function, and their lives. I appreciate your commitment to this important work.

Disclosures, Safety, and Individualization

• Some medications discussed (e.g., metformin for prediabetes/PCOS without diabetes) may be off-label; we follow current guidelines and evidence, discuss risks/benefits, and obtain informed consent.
• GLP-1/GIP therapies require contraceptive planning; we advise barrier methods during initiation and titration if using oral contraceptives due to delayed gastric emptying considerations referenced in product information.
• Lisdexamfetamine is FDA-approved for binge-eating disorder but demands careful cardiovascular and psychiatric monitoring.

References

• Abi Nader, M. A., et al. (2022). Continuous glucose monitoring in metabolic health and precision nutrition. Nutrients, 14(3), 651.
• Adam, T. C., & Epel, E. S. (2007). Stress, eating and the reward system. Physiology & Behavior, 91(4), 449-458.
• American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care.
• Asarian, L., & Geary, N. (2013). Sex differences in the physiology of eating. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 305(11), R1215-R1267.
• Athauda, D., & Foltynie, T. (2016). The glucagon-like peptide 1 (GLP-1) receptor as a therapeutic target in PParkinson’sdisease: Mechanisms of action. Drug Discovery Today, 21(5), 802-818.
• Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., & Lizneva, D. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers.
• Bakris, G., Dickholtz, M., Meyer, P. M., Kravitz, G., Avery, E., Miller, M., Brown, J., Woodfield, C., & Bell, B. (2007). Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: A pilot study. Journal of Human Hypertension, 21(5), 347-352.
• Berthoud, H.-R. (2011). Metabolic and hedonic drives in the neural control of appetite. American Journal of Physiology.
• Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Levesque, H., Trillot, N., Barrellier, M. T., Wahl, D., Emmerich, J., & Scarabin, P. Y. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation, 115(7), 840-845.
• Carbone, J. W., & Pasiakos, S. M. (2019). Dietary protein and muscle mass: Translating science to application and health benefit. Nutrients, 11(5), 1136.
• Cawley, J., & Meyerhoefer, C. (2012). The medical care costs of obesity: An instrumental variables approach. Journal of Health Economics, 31(1), 219-230.
• Centers for Disease Control and Prevention. (2022). National diabetes statistics report. U.S. Department of Health and Human Services.
• Churchward-Venne, T. A., Holwerda, A. M., Phillips, S. M., & van Loon, L. J. C. (2016). What is the optimal amount of protein to support post-exercise skeletal muscle reconditioning in the older adult? Sports Medicine, 46(9), 1205-1212.
• Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., & Ploj, K. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(7), 1045-1065.
• Davis, S. R., Castelo-Branco, C., Chedraui, P., Lumsden, M. A., Nappi, R. E., Shah, D., & Villaseca, P. (2012). Understanding weight gain at menopause. Climacteric, 15(5), 419-429.
• DiPietro, L., Gribok, A., Stevens, M. S., Hamm, L. F., & Rumpler, W. (2013). Three 10-min bouts of postprandial walking reduce glucose excursions. Diabetes Care.
• Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome. Endocrine Reviews.
• Estruch, R., Ros, E., Salas-Salvado, J., Covas, M. I., Corella, D., Aros, F., Gomez-Gracia, E., Ruiz-Gutierrez, V., Fiol, M., Lapetra, J., Lamuela-Raventos, R. M., Serra-Majem, L., Pinto, X., Basora, J., Munoz, M. A., Sorli, J. V., Martinez, J. A., Fito, M., Gea, A., … & Martinez-Gonzalez, M. A. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378(25), e34.
• Fairburn, C. G. (2008). Cognitive behavior therapy and eating disorders. Guilford Press.
• Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., et al. (2012). Consensus on women’s health aspects of PCOS. Human Reproduction.
• Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in type 2 diabetes. NEJM.
• Goodman, N. F., Cobin, R. H., Futterweit, W., et al. (2015). AACE/ACE/Androgen Excess Society position statement on PCOS. Endocrine Practice.
• Guerin, V., & Billes, S. K. (2016). Naltrexone/Bupropion for the treatment of obesity. Current Diabetes Reviews, 12(3), 229–241.
• Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., … & Zundel, N. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open, 5(9), e2231982-e2231982.
• Gutch, M., Kumar, S., Razi, S. M., Gupta, K. K., & Gupta, A. (2015). Assessment of insulin sensitivity/resistance. Indian Journal of Endocrinology and Metabolism, 19(1), 160–164.
• Hall, K. D., & Guo, J. (2017). Obesity energetics: Body weight regulation and the effects of diet composition. Gastroenterology.
• Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2020). Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief, No. 360. National Center for Health Statistics.
• Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Sann, H., … & ESSENCE Study Group. (2023). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine, 390(6), 497-509.
• Herman, B. K., et al. (2016). Validity of the BEDS-7. Primary Care Companion CNS Disorders.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
• Katib, A. (2015). Mechanisms linking obesity to male infertility. Central European Journal of Urology, 68(1), 79–85.
• Kershaw, E. E., & Flier, J. S. (2004). Adipose tissue as an endocrine organ. J Clin Endocrinol Metab.
• Kim, C., Newton, K. M., & Knopp, R. H. (2019). Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care.
• Knop, F. K., Vilsboll, T., Hojberg, P. V., Larsen, S., Madsbad, S., Volund, A., Holst, J. J., & Krarup, T. (2007). Reduced incretin effect in type 2 diabetes: Cause or consequence of the diabetic state? Diabetes, 56(8), 1951-1959.
• Knowler, W. C., Barrett-Connor, E., Fowler, S. E., et al. (2002). Diabetes Prevention Program outcomes. NEJM.
• Leidy, H. J., et al. (2015). The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition.
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornoe, C. W., Ryan, D. H., & SELECT Trial Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Margolis, K. L., Wassertheil-Smoller, S., Beresford, S. A., Cauley, J. A., Eaton, C. B., Gass, M., … & Wallace, R. B. (2017). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 318(10), 927-938.
• Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013). The role of estrogens in control of energy balance and glucose homeostasis. Endocrine Reviews, 34(3), 309-338.
• McElroy, S. L., Hudson, J. I., Mitchell, J. E., et al. (2015). Efficacy of lisdexamfetamine in binge eating disorder. JAMA Psychiatry.
• Mendelsohn, M. E., & Karas, R. H. (1999). The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine, 340(23), 1801-1811.
• Montani, J.-P., Schutz, Y., & Dulloo, A. G. (2015). Dieting and weight cycling: Health impacts. Obesity Reviews.
• Montorsi, P., Montorsi, F., & Schulman, C. C. (2003). Is erectile dysfunction the “tip of the iceberg” of a systemic vascular disorder? European Urology, 44(3), 352-354.
• Moran, L. J., et al. (2011). Diet and lifestyle in PCOS. Human Reproduction Update.
• Morley, L. C., Tang, T., et al. (2017). Insulin-sensitizing drugs in PCOS. Human Reproduction Update.
• Ponti, F., Santoro, A., Mercatelli, D., Gasperini, C., Conte, M., Martucci, M., … & Franceschi, C. (2020). Aging and imaging assessment of body composition: from fat to facts. Frontiers in endocrinology, 10, 861.
• Puhl, R. M., & Heuer, C. A. (2009). The stigma of obesity: a review and update. Obesity, 17(5), 941-964.
• Romero-Corral, A., Caples, S. M., López-Jiménez, F., & Somers, V. K. (2010). Interactions between obesity and obstructive sleep apnea: Implications for treatment. Chest, 137(3), 711-719.
• Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13), 1465-1477.
• Rubino, D. M., Greenway, F. L., Kent, K., Arslanian, S., Tchang, B. G., & Wadden, T. A. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138-150.
• Ryan, D. H., & Yockey, S. R. (2017). Weight Loss and Improvement in Comorbidities: Differences at 5%, 10%, 15%, and Over. Current obesity reports, 6(2), 187-194.
• Santoro, N., Roeca, C., Peters, B. A., & Neal-Perry, G. (2021). The menopause transition: Signs, symptoms, and management options. Journal of Clinical Endocrinology & Metabolism, 106(1), 1-15.
• Sipila, S., Tormakangas, T., Sillanpaa, E., Aukee, P., Kovanen, V., Narici, M. V., & Laakkonen, E. K. (2021). Muscle and bone mass in middle-aged women: Role of menopausal status and physical activity. Journal of Cachexia, Sarcopenia and Muscle, 12(2), 285-294.
• Stárka, L., & Duskova, M. (2015). What is a hormone? Physiological Research, 64(Suppl 2), S133-S140.
• Stoppel, C., et al. (2023). Semaglutide for alcohol use disorder (STAR trial). ClinicalTrials.gov identifier: NCT05421377.
• Taheri, S., et al. (2004). Short sleep duration and leptin/ghrelin changes. PLoS Medicine.
• Taylor, S. I. (2021). Insulin resistance mechanisms in humans. Endocrine Reviews.
• The North American Menopause Society. (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 29(7), 767-794.
• Wilding, J. P. H., Batterham, R. L., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. NEJM.
• Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology, 77(4), 1335-1347.
• Zhang, J., Dean, D., Nosco, D., Strathopulos, D., & Floros, M. (2006). Effect of chiropractic care on heart rate variability and pain in a multisite clinical study. Journal of Manipulative and Physiological Therapeutics, 29(4), 267-274.

SEO Tags: perimenopause hormone therapy, menopausal hormone therapy El Paso, tirzepatide weight loss, semaglutide cardiovascular outcomes, GLP-1 receptor agonist, sarcopenic obesity treatment, type 2 diabetes insulin deprescribing, integrative chiropractic care metabolic disease, functional medicine El Paso Texas, body composition monitoring obesity, obesity medicine shared decision making, incretin based therapy mechanism of action, Dr Alex Jimenez DC APRN, Injury Medical Clinic PA El Paso, Dr Maria Cardenas MD internal medicine El Paso, peripheral artery disease exercise therapy, MASLD treatment semaglutide, muscle mass preservation GLP-1 therapy, food noise GLP-1, Mediterranean diet type 2 diabetes, sarcopenia resistance training protein intake, dual incretin agonist tirzepatide mechanism, SELECT trial semaglutide cardiovascular, chiropractic autonomic nervous system, weight management multidisciplinary care, integrative medicine obesity, cardiometabolic risk reduction El Paso, perimenopausal weight gain estrogen, transdermal estradiol perimenopause, obesity hormonal disease biology, PCOS treatment, insulin resistance, GLP-1 therapy, metformin, binge eating disorder, lisdexamfetamine, women’s health, fertility and PCOS, HOMA-IR, A1c improvement, dyslipidemia, metabolic syndrome, postprandial walking, protein-forward diet, sciatica clinic, El Paso chiropractor, Mission Plaza Injury Medical Clinic, Male Infertility, Prediabetes, Hypertension, Low Testosterone, Bupropion-Naltrexone, Stress Management, Visceral Fat, Osteoarthritis, Knee Replacement, Weight Bias in Healthcare, Patient-Centered Care, Phentermine, Cardiometabolic Syndrome, Musculoskeletal Health, Personal Injury Clinic